Characteristics for patients with SLE (n=102) included in the study at baseline
| Demographics | Mean±SD or N (%) |
| Age, years | 49.98±14.58 |
| Gender, female | 85 (83.33) |
| BMI | 25.49±4.66 |
| Disease duration, years, n=98 | 10.63±12.07 |
| Onset | |
| Incident | 29 (28.43) |
| Prevalent | 73 (71.57) |
| APS | 16 (15.69) |
| Diabetes | 3 (2.94) |
| Dyslipidaemia | 8 (7.84) |
| ACR criteria n=99 | n (%) |
| Arthritis | 79 (77.45) |
| Thrombocytopaenia | 24 (23.53) |
| Malar rash | 26 (25.49) |
| Discoid rash | 18 (17.65) |
| Haemolytic anaemia | 4 (3.92) |
| Renal disorder | 25 (24.51) |
| Medication | n (%) |
| NSAID/Cox-II inhibitors | 25 (24.51) |
| Antimalarials | 77 (75.49) |
| Immunomodulators | 86 (84.31) |
| Methotrexate | 16 (15.69) |
| Biologic agents | 7 (6.86) |
| Steroids | 22 (21.57) |
| Other DMARD | 28 (27.45) |
| Prednisone | 21 (20.59) |
| Clinical characteristics | Mean±SD or n (%) |
| SLEDAI, n=99 | 3.07±3.70 |
| Platelet, 109 /L, n=101 | 227.20±74.91 |
| MPV, fL, n=101 | 8.92±6.10 |
| Haemoglobin, g/L, n=101 | 129.34±12.29 |
| CRP, mg/L, n=82 | 4.47±7.25 |
| ESR, mm/hour, n=94 | 13.55 |